Nifelat La (Nifedipine)

Nifedipine blocks L‑type calcium channels on vascular smooth‑muscle cells. By preventing calcium entry, the muscle cannot contract effectively, leading to dilation of arteries, lower peripheral resistance, and a reduction in blood pressure and cardiac workload.

The exact dose of Nifelat La is determined by the prescribing clinician based on the patient’s condition, response, and other medical factors. Healthcare professionals tailor the regimen to achieve optimal blood‑pressure control or angina relief while minimizing side effects.

Safety data for nifedipine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nifedipine belongs to the dihydropyridine class of calcium‑channel blockers, offering potent arterial vasodilation. Compared with beta‑blockers, it primarily reduces peripheral resistance rather than heart rate, and unlike ACE inhibitors, it does not affect the renin‑angiotensin system. Choice depends on patient profile and comorbidities.

Store Nifelat La at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture, heat and direct sunlight. Do not store in a refrigerator or freezer unless specifically instructed by the supplier.

Nifelat La is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless the prescriber advises otherwise. Dosing frequency and timing are set by the treating physician based on therapeutic goals.

Serious adverse events include severe hypotension, myocardial infarction, hepatic dysfunction, and allergic reactions such as rash or anaphylaxis. Patients should seek immediate medical attention if they experience sudden dizziness, fainting, chest pain, yellowing of the skin or unexplained swelling.

Nifelat La is contraindicated in patients with known hypersensitivity to nifedipine or any other dihydropyridine calcium‑channel blockers. It should also be avoided in individuals with severe aortic stenosis, uncontrolled heart failure, or those taking potent CYP3A4 inhibitors without close monitoring.